Drug Profile
S 055746
Alternative Names: BCL-201; S 055746; S-55746; Servier-1Latest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator Servier; Vernalis
- Developer Novartis Pharmaceuticals Corporation; Servier; Vernalis
- Class Antineoplastics; Small molecules
- Mechanism of Action Apoptosis stimulants; Proto-oncogene protein c-bcl-2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Follicular lymphoma; Mantle-cell lymphoma; Multiple myeloma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Small cell lung cancer
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for phase-I development in Multiple-myeloma in Unknown (PO)
- 28 Jun 2023 No recent reports of development identified for preclinical development in Acute-myeloid-leukaemia in United Kingdom (PO)
- 28 Apr 2023 No recent reports of development identified for preclinical development in Small-cell-lung-cancer in USA (PO, Tablet)